HOME >> MEDICINE >> NEWS
Pharmaceutical industry still failing health needs of less-developed countries

The third article about the role of the pharmaceutical industry in medicine--The Pharmaceutical Industry as a Medicines Provider--is published in this week's issue of THE LANCET.

David Henry from the University of Newcastle, Australia, and Joel Lexchin from the University of Toronto, Canada, discuss how rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, they state, millions of individuals do not have access to essential drugs, and drug development is failing to address the major health needs of these countries. The authors also comment how the prices of patented medicines usually far exceed the marginal costs of their production -- while the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products, there are doubts about the figures that form the basis of these claims.

David Henry comments: "The international pharmaceutical industry manufactures and distributes many good drugs, displays generosity in its philanthropic activities, and has an important role in maintenance of manufacturing standards. However, evidence shows that companies have shifted their core activities from discovery and development of innovative drugs to marketing of products that keep profit to a maximum in high-income countries."

He adds: "Access to important drugs by low-income countries is generally agreed to remain grossly inadequate. Some international manufacturers have responded to this crisis by sharp reductions in prices of some products and by donations. These moves largely seem to have been in response to external pressures, especially bad publicity and generic competition, rather than initiatives of the companies themselves. Restoration of true market forces and fair pricing of drugs is a better long term solution to shortages than 'ad hoc' donations. These issues are particularly relevant and timely
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
14-Nov-2002


Page: 1 2

Related medicine news :

1. Pharmaceutical marketing tactics hold little sway with prescribing physicians
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Pharmaceutical Achievers
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
7. American Association of Pharmaceutical Scientists Dietary Supplements Forum examines science behind nutraceuticals
8. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
9. Pharmaceuticals and personal care products
10. New publisher announced for Journal Of Pharmaceutical Sciences
11. American Association of Pharmaceutical Scientists tapped to manage PQRI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... Urologix, the market leader for in-office minimally ... Hyperplasia (BPH), announces new private ownership and is operating ... device industry veteran of more than 20 years, has ... Plymouth, Minn. The company,s ... Prostiva® RF Therapy, will continue to be broadly available ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology:
Cached News: